Xiangjun Zheng

A multicenter, open‐label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma

J. Hou, X. Ke, L. Qiu, 2014, American journal of hematology.

A Phase1b Dose Escalation Study of Recombinant Circularly Permuted TRAIL in Patients With Relapsed or Refractory Multiple Myeloma

J. Hou, L. Qiu, Wenming Chen, 2017, American journal of clinical oncology.

Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study

Yan Liu, Hua Jiang, B. Jiang, 2017, Cancer Chemotherapy and Pharmacology.

Transiently Elevated AST/LDH Are Associated with Clinical Response to Recombinant Circularly Permuted TRAIL (CPT) Plus Thalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma

J. Hou, X. Ke, L. Qiu, 2014 .

Circularly Permuted TRAIL (CPT) combined with Thalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma: An Open-Label, Multicenter Phase II Clinical Trial.

J. Hou, X. Ke, L. Qiu, 2012 .